Zimmer Biomet to Release New Data, Highlight Key Innovations at American Academy of Orthopaedic Surgeons Annual Meeting

Rhea-AI Summary

Zimmer Biomet (NYSE: ZBH) will present new clinical and operational data and showcase robotic, digital and implant innovations at the AAOS 2026 Annual Meeting on March 5-9, 2026. The company will feature products including ROSA Knee with OptimiZe, Persona IQ, Monogram TKA, Oxford Cementless Partial Knee and Z1 Femoral Hip.

Arnold Schwarzenegger will appear as the conference Presidential Guest Speaker on March 5 at 10:30 a.m. CT alongside CEO Ivan Tornos and AAOS President Ned Amendola; multiple poster and data presentations will address safety, gait metrics, readmissions and ASC efficiency.

News Market Reaction – ZBH

-0.02%

1 alert

-0.02% News Effect

On the day this news was published, ZBH declined 0.02%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

AAOS 2026 keynote time: 10:30 a.m. Central Time AAOS booth number: 4239 Oxford knee heritage: 50 years +2 more

5 metrics

AAOS 2026 keynote time 10:30 a.m. Central Time Presidential Guest Speaker session on March 5, 2026

AAOS booth number 4239 Zimmer Biomet exhibit location at AAOS 2026 Annual Meeting

Oxford knee heritage 50 years Clinical heritage of Oxford Partial Knee system

90-day readmissions window 90 days Association between readmissions and early post-op step counts after TKA

Magnificent Seven set Seven technologies Zimmer Biomet’s most differentiated orthopedic technologies grouping

Market Reality Check

Price: $100.99 Vol: Volume 1,498,570 vs 20-da...

low vol

$100.99 Last Close

Volume Volume 1,498,570 vs 20-day average 2,393,388, at 0.63x typical trading activity. low

Technical Price 99.87 is trading above 200-day MA of 95.24 and 12.73% below 52-week high.

Peers on Argus

ZBH gained 0.41% while key peers were mixed: SNN -1.21%, PODD -0.85%, DXCM -0.30...

1 Down

ZBH gained 0.41% while key peers were mixed: SNN -1.21%, PODD -0.85%, DXCM -0.30%, STE +0.25%, indicating a stock-specific tilt to this AAOS conference update.

Historical Context

5 past events · Latest: Feb 23 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 23	Quarterly dividend	Positive	+0.7%	Announced Q1 2026 cash dividend of $0.24 per share with set record date.
Feb 10	Earnings results	Positive	+1.9%	Reported Q4 and FY 2025 sales, EPS and 2026 guidance plus $1.5B buyback.
Jan 15	Earnings call setup	Neutral	-0.6%	Scheduled Q4 2025 earnings webcast and provided dial-in and access details.
Dec 22	Conference appearance	Neutral	+0.8%	Announced management presentation at 44th J.P. Morgan Healthcare Conference.
Dec 17	Quarterly dividend	Positive	+0.7%	Declared Q4 2025 cash dividend of $0.24 per share with payable and record dates.

Pattern Detected

Recent news (earnings, dividends, conferences) has often coincided with modest positive price reactions, with occasional divergences on neutral conference-related items.

Recent Company History

Over the past few months, Zimmer Biomet has focused on capital returns and communication with investors. Two dividend announcements in Dec 2025 and Feb 2026 and a new quarterly dividend for Q1 2026 all saw modest gains. The Q4 and full-year 2025 earnings release with detailed sales and EPS metrics also moved shares higher. Neutral events such as the J.P. Morgan conference presentation and the Q4 call scheduling saw smaller, mixed reactions. Today’s AAOS innovation and data preview fits within this pattern of ongoing engagement and product-focused visibility.

Market Pulse Summary

This announcement highlights Zimmer Biomet’s emphasis on robotics, AI and smart implantable devices,...

Analysis

This announcement highlights Zimmer Biomet’s emphasis on robotics, AI and smart implantable devices, with new data spanning Oxford Cementless Partial Knee safety and efficacy, ASC workflow efficiency, and post-operative gait and step-count metrics. Positioned around the AAOS 2026 Annual Meeting, it reinforces the company’s focus on digital and robotic ecosystems across knee, hip and extremity reconstruction. Investors may watch for future disclosures that quantify clinical outcomes, readmission reductions, and efficiency gains, as well as how these innovations support broader growth targets and capital return plans outlined in recent earnings updates.

Key Terms

total knee arthroplasty, 510(k) clearance, venous thromboembolisms, periprosthetic joint infections, +3 more

7 terms

total knee arthroplasty medical

"Monogram Technologies TKA System: A CT-based, semi-autonomous, total knee arthroplasty (TKA) robotic technology"

Total knee arthroplasty is a surgical procedure that replaces a damaged knee joint with artificial components to restore motion and reduce pain — think of swapping out a worn door hinge for a new one. It matters to investors because demand, costs, and outcomes for this common, often elective surgery affect makers of implants and instruments, hospitals, insurers, and companies involved in rehabilitation and medical devices.

510(k) clearance regulatory

"robotic technology that received U.S. Food and Drug Administration (FDA) 510(k) clearance in March 2025"

A 510(k) clearance is a U.S. regulatory approval that lets a medical device be sold because it is shown to be substantially similar to an already-legal device; think of it as a passport saying the new product is close enough to a known item to enter the market without a full, lengthy review. For investors, 510(k) clearance signals faster, lower-cost market access and reduced regulatory risk compared with new, untested device pathways, which can materially affect timelines, costs and revenue prospects.

venous thromboembolisms medical

"qualified step counts ... and venous thromboembolisms (blood clots) following primary TKA"

Venous thromboembolisms are blood clots that form in veins, commonly starting in deep leg veins and sometimes breaking loose to block blood flow in the lungs (a pulmonary embolism). Investors care because VTEs drive demand for drugs, devices and hospital care, influence clinical trial results and regulatory decisions, and can create sudden costs or liability for healthcare companies—like an unexpected roadblock that reshapes a firm’s financial outlook.

periprosthetic joint infections medical

"relationship between early gait decline ... and periprosthetic joint infections in total knee arthroplasty"

An infection that develops in the tissues surrounding a replaced joint, such as a hip or knee implant. Think of it like mold growing around a replaced part in a house: it can damage the replacement, require long courses of antibiotics, additional surgeries to remove or replace the implant, and extended hospital stays. For investors, these infections drive higher treatment costs, affect device recall or redesign risk, and influence demand and regulatory scrutiny in the orthopedic market.

ambulatory surgery centers medical

"Efficiency improvement metrics when implementing new processes and workflows in ambulatory surgery centers (ASCs)"

Ambulatory surgery centers are medical facilities where patients undergo planned surgical or diagnostic procedures and leave the same day, without an overnight hospital stay. They matter to investors because they often deliver care more cheaply and efficiently than full hospitals, which can boost patient volume and profit margins; changes in insurance reimbursement, regulation, or patient preference can therefore directly affect revenue and growth potential.

arthroplasty medical

"total knee arthroplasty (TKA) robotic technology that received U.S. Food and Drug Administration"

Arthroplasty is a surgical procedure that replaces or repairs a damaged joint — commonly the hip or knee — by fitting an artificial joint or resurfacing the joint surface, much like replacing a worn hinge on a door so it moves smoothly again. Investors care because the procedure drives demand for medical devices, hospital services, implants, and follow-up care; trends in procedure volume, technology improvements, reimbursement rates, and aging populations can directly affect revenues and costs across healthcare companies and insurers.

fluoroscopy-based technical

"OrthoGrid Hip AI: An AI-powered, fluoroscopy-based technology that provides hip surgeons"

Using fluoroscopy-based technology means a procedure or device relies on continuous X‑ray imaging to produce live, moving pictures of the inside of the body—like watching a real‑time X‑ray movie. For investors, this matters because such products often involve higher-cost equipment, specific regulatory and safety requirements, specialist training and reimbursement pathways, all of which affect adoption speed, recurring revenue and liability risk.

AI-generated analysis. Not financial advice.

Company's Chief Movement Officer, Arnold Schwarzenegger,
Will Be Presidential Guest Speaker

WARSAW, Ind., Feb. 25, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced it will unveil new clinical and operational data and showcase its newest innovations at the American Academy of Orthopaedic Surgeons (AAOS) 2026 Annual Meeting. The company's Chief Movement Officer Arnold Schwarzenegger will take center stage as the conference's Presidential Guest Speaker.

On Thursday, March 5 at 10:30 a.m. Central Time, Schwarzenegger will be featured as the Presidential Guest Speaker, and will join Zimmer Biomet Chairman, President and CEO Ivan Tornos and AAOS President Ned Amendola, MD, FAAOS, FRCSC, DABOS, for a main-stage conversation about sustaining peak performance, teamwork and thriving under pressure.

"Our presence at the AAOS Annual Meeting will highlight Zimmer Biomet's leadership in orthopedic implants coupled with the robotic and digital technologies that collect data before, during and after surgery to provide insights that help surgeons understand the potential impact of surgical decisions on patient outcomes," said Tornos. "In addition to the technologies we plan to showcase and new data being presented, we are very proud to feature our Chief Movement Officer, Arnold Schwarzenegger, as the Presidential Guest Speaker, and I look forward to joining him and Dr. Amendola for an engaging discussion."

The company will highlight its wide variety of orthopedic innovations and solutions at booth 4239, including its most differentiated technologies that have built a reputation as the "Magnificent Seven," including:

• Robotics and Navigation Technologies: From CT, to imageless to handheld robotics and AI-driven navigation technologies, Zimmer Biomet offers the industry's most comprehensive and adaptable suite of orthopedic robotics and navigation technologies designed to elevate surgical precision and transform patient outcomes.
  • ROSA^® Knee with OptimiZe™: The newest version of the ROSA^® Knee System to customize and enhance the surgeon's experience with personalized and intelligent surgical planning, new positioning, tracking and alignment features to improve accuracy¹ and reduce user variability² — and offers the industry's only automated kinematic alignment feature to resurface the knee with the goal of restoring its pre-arthritic position and native joint lines.
  • TMINI^® Miniature Robotic System: A state-of-the-art miniature, handheld, wireless CT-based robotic system designed to enable accurate and precise³ implant placement.
  • Monogram Technologies TKA System: A CT-based, semi-autonomous, total knee arthroplasty (TKA) robotic technology that received U.S. Food and Drug Administration (FDA) 510(k) clearance in March 2025. A surgeon-guided, fully autonomous version of this technology is currently in clinical trials.
  • OrthoGrid Hip AI^®: An AI-powered, fluoroscopy-based technology that provides hip surgeons with intuitive and instantaneous intra-operative tools to assist surgeons in achieving the desired surgical outcomes for component positioning.⁴
    
    
• Oxford^® Cementless Partial Knee: Celebrating 50 years of clinical heritage, the Oxford Partial Knee is the most widely used⁵ and clinically proven^6,7 partial knee system in the world. It is also the only FDA-approved mobile cementless partial knee implant in the U.S. that has been shown to be efficient^8,9 in the operating room and has been proven to have excellent survivorship^10,11 worldwide.
  
  
• Z1^® Femoral Hip System: Offers an expansive size range and three distinct neck options designed to address a variety of patient anatomies and reconstructive needs.
  
  
• Persona IQ^® The Smart Knee^®: The first and only smart knee implant that captures patient-specific gait and range of motion metrics directly from the knee during patient monitoring to provide post-operative recovery insights^12,13 and trends, allowing care teams to monitor and personalize the TKA patient experience.^10-14
  
  
• Persona^® OsseoTi^® Keel Tibia: A cementless tibia for TKA with a 3D printed porous tray that provides stable initial and biological fixation and intra-operative versatility.¹⁵
  
  
• HAMMR^® Automated Hip Impaction System: Designed to address surgeon strain, fatigue and repetitive motion associated with the traditional mallet during hip replacement procedures, and provides a consistent, controlled and precise energy¹⁶ designed to minimize variability in both bone preparation and device implantation.
  
  
• Persona^® Revision Knee System: Expands the Persona Knee System to provide a portfolio of personalized knee care to replicate a patient's anatomy and offer an individualized fit in partial, primary and revision knee arthroplasties.

New data being presented at the conference will highlight:

• Safety and efficacy data for the Oxford^® Cementless Partial Knee;
• Efficiency improvement metrics when implementing new processes and workflows in ambulatory surgery centers (ASCs);
• The relationship between early gait decline (collected with a smart implantable device) and periprosthetic joint infections in total knee arthroplasty (TKA);
• The relationship between qualified step counts (collected with a smart implantable device) and venous thromboembolisms (blood clots) following primary TKA;
• How the use of a smart implantable device and a digital care platform was associated with lower post-operative complications in knee replacement procedures;
• The association between 90-day readmissions and immediate post-operative qualified step counts (collected with a smart implantable device) following primary TKA; and
• New thresholds for post-operative gait metrics to help assess clinical significance in joint replacement patients.

Zimmer Biomet exhibit will also feature the latest innovations in shoulder reconstruction, sports medicine, trauma, foot and ankle reconstruction from the company's recent Paragon 28 acquisition, along with solutions for infection prevention and the company's ZBX^™ Ambulatory Surgery Center Solutions (ASCs) — a comprehensive approach to help surgeons locate, design, build and operate ASCs.

About Zimmer Biomet
Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.

With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation. 

For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow on LinkedIn at www.linkedin.com/company/zimmerbiomet or X at www.x.com/zimmerbiomet.

Persona IQ: The objective kinematic data generated by the CSE with CHIRP System are not intended to support clinical decision-making and have not been shown to provide any clinical benefit.

Cautionary Statement Regarding Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning Zimmer Biomet's expectations, plans, prospects, and product and service offerings, including new product launches and potential clinical successes. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially. For a list and description of some of such risks and uncertainties, see Zimmer Biomet's periodic reports filed with the U.S. Securities and Exchange Commission (SEC). These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet's filings with the SEC. Forward-looking statements speak only as of the date they are made, and Zimmer Biomet disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this news release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this news release.

Contacts:
Media	Investors
Troy Kirkpatrick	David DeMartino
614-284-1926	646-531-6115
troy.kirkpatrick@zimmerbiomet.com	david.demartino@zimmerbiomet.com
Kirsten Fallon	Zach Weiner
781-779-5561	908-591-6955
kirsten.fallon@zimmerbiomet.com	zach.weiner@zimmerbiomet.com

¹ Data on File. DVaR-DS250106-01 ROSA Knee System v1.5 Validation Report.
² Data on File. FER-EMS230714-01 Formative Evaluation Report - July Lab 2023.
³ Data on file at THINK Surgical. 2024. Data is based on TMINI System assisted placement of cut guide compared to planned placement.
⁴ Cardenas JM, Gordon D, Waddell BS, Kitziger KJ, Peters PC Jr, Gladnick BP. Does Artificial Intelligence Outperform Humans Using Fluoroscopic-Assisted Computer Navigation for Total Hip Arthroplasty? Arthroplasty Today. 2024 May 27;27:101410. doi: 10.1016/j.artd.2024.101410. PMID: 38840694; PMCID: PMC11150909.
⁵ Data on file at Zimmer Biomet. Based on Market Analysis and Registry Data, gathered September 2017.
⁶ Price, A. and Svard, U. A Second Decade Lifetable Survival Analysis of the Oxford Unicompartmental Knee Arthroplasty. Clin Orthop Relat Res. 2011 Jan;469(1): 174-9.
⁷ Pandit et al. The clinical outcome of minimally invasive phase 3 Oxford unicompartmental knee arthroplasty. Bone Joint J 2015;97-B:1493–1500.
⁸ Pandit, H., et al. "Improved fixation in cementless unicompartmental knee replacement: five-year results of a randomized controlled trial." JBJS 95.15 (2013): 1365-1372.
⁹ Stempin R, Kaczmarek W, Stempin K, Dutka J. Midterm Results of Cementless and Cemented Unicondylar Knee Arthroplasty with Mobile Meniscal Bearing: A Prospective Cohort Study. Open Orthop J. 2017 Oct 31;11:1173-1178. doi: 10.2174/1874325001711011173. PMID: 29290853; PMCID: PMC5721307.
¹⁰ NJR- UK . The National Joint Registry 22nd Annual Report 2025 London, 2024 [Available from: https://reports.njrcentre.org.uk/Portals/0/PDFdownloads/NJR%2022nd%20Annual%20Report%202025_Knees.pdf.
¹¹ AOANJRR. Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR). Hip, Knee & Shoulder Arthroplasty: 2023 Annual Report Adelaide, AOA2024 [updated 2024. Available from: https://aoanjrr.sahmri.com/documents/10180/1798900/AOANJRR+2024+Annual+Report.pdf/9d0bfe03-2282-8fc8-a424-b8d9abb82b1f?t=1727666185313.
¹² Cushner FD, Yergler J, ElashoffB, Aubin PM, VertaP, Scuderi GR. Staying Ahead of the Curve: The Case for Recovery Curves in Total Knee Arthroplasty. The Journal of Arthroplasty. 2024;doi:10.1016/j.arth.2024.07.039
¹³ Cushner FD, Sculco PK, Long WJ. The Talking Knee Is a Reality: What Your Knee Can Tell You After Total Knee Arthroplasty. J OrthopaedicExperience and Innovation. 2022;2022
¹⁴ Cushner FD, Schiller P, Gross J, Mueller JK, Hunter W. A Total Knee Arthroplasty Prosthesis Capable of Remote Patient Monitoring. OrthopaedicProceedings. 2021/06/01 2021;103-B(SUPP_9):18-18 doi:10.1302/1358-992X.2021.9.018
¹⁵ Mueller J.K., et al. Persona OsseoTi Keel Tibia Provides Stable Initial Fixation 4027.2-GLBL-en. November 2022.
¹⁶ Data on File at Zimmer Biomet. Zimmer HAMMR Verification Test Report. DOC0179677. Pages 47-49. January 19, 2024.

View original content to download multimedia:https://www.prnewswire.com/news-releases/zimmer-biomet-to-release-new-data-highlight-key-innovations-at-american-academy-of-orthopaedic-surgeons-annual-meeting-302696434.html

SOURCE Zimmer Biomet Holdings, Inc.

FAQ

When will Zimmer Biomet (ZBH) present at AAOS 2026 and who will speak?

Zimmer Biomet will appear at AAOS 2026 with a main-stage session on March 5, 2026 at 10:30 a.m. CT. According to Zimmer Biomet, Arnold Schwarzenegger will be the Presidential Guest Speaker and will join CEO Ivan Tornos and AAOS President Ned Amendola for the discussion.

What new clinical topics will Zimmer Biomet (ZBH) present at AAOS 2026?

Zimmer Biomet will present safety and efficacy data for the Oxford Cementless Partial Knee and gait-related analyses after TKA. According to Zimmer Biomet, presentations will cover gait decline, step counts, readmissions, infection links and complication associations from smart implant data.

Which Zimmer Biomet (ZBH) robotic and smart technologies will be showcased at AAOS 2026?

The exhibit will showcase ROSA Knee with OptimiZe, TMINI miniature robot, Monogram TKA system, OrthoGrid Hip AI and Persona IQ. According to Zimmer Biomet, the portfolio spans CT-based, imageless and handheld robotics plus AI navigation and smart implants.

Did Zimmer Biomet (ZBH) receive FDA clearance for any showcased technology?

Yes. According to Zimmer Biomet, the Monogram Technologies TKA System received U.S. FDA 510(k) clearance in March 2025. The company says a surgeon-guided fully autonomous version of Monogram is currently in clinical trials.

How will Zimmer Biomet (ZBH) address ambulatory surgery center (ASC) efficiency at AAOS 2026?

Zimmer Biomet will present metrics showing efficiency improvements from new ASC processes and workflows. According to Zimmer Biomet, the company will highlight ZBX ASC Solutions and data on operational gains when implementing those approaches in ambulatory settings.

What implant milestones and acquisitions will Zimmer Biomet (ZBH) highlight at AAOS 2026?

Zimmer Biomet will mark the Oxford Partial Knee's 50-year clinical heritage and showcase Paragon 28 shoulder and extremity solutions. According to Zimmer Biomet, the exhibit will include the Oxford Cementless Partial Knee and Paragon 28 technologies for shoulder, trauma and foot/ankle.